Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nature Rev Dis Primers. 2015;1(1):15067.

Article  Google Scholar 

Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;386(9995):743–800.

Article  Google Scholar 

Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.

Article  PubMed  Google Scholar 

Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002;14(2):123–9.

Article  PubMed  Google Scholar 

Abouzaid S, Tian H, Zhou H, Kahler KH, Harris M, Kim E. Economic burden associated with extrapyramidal symptoms in a medicaid population with Schizophrenia. Community Ment Health J. 2014;50(1):51–8.

Article  PubMed  Google Scholar 

Pierre JM. Extrapyramidal symptoms with atypical antipsychotics. Drug Saf. 2005;28(3):191–208.

Article  CAS  PubMed  Google Scholar 

Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ogino S, Miyamoto S, Miyake N, Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014;68(1):37–49.

Article  CAS  PubMed  Google Scholar 

Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic medication burden-associated cognitive impairment in Schizophrenia. Am J Psychiatry. 2021;178(9):838–47.

Article  PubMed  PubMed Central  Google Scholar 

Solmi M, Pigato G, Kane JM, Correll CU. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21–7.

Article  PubMed  Google Scholar 

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084–93.

Article  PubMed  PubMed Central  Google Scholar 

Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361: k1315.

Article  PubMed  PubMed Central  Google Scholar 

Majer IM, Gaughran F, Sapin C, Beillat M, Treur M. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Market Access Health Policy. 2015;3(1):27208.

Article  Google Scholar 

Haddad PM, Correll CU. Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. Expert Opin Pharmacother. 2023;24(4):473–93.

Article  CAS  PubMed  Google Scholar 

Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in Schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.

Article  PubMed  Google Scholar 

Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64(Suppl 16):34–40.

PubMed  Google Scholar 

Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psych. 2021;8(5):387–404.

Article  Google Scholar 

Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psych. 2022;21(2):248–71.

Article  Google Scholar 

Álamo C. Risperidone ISM as a new option in the clinical management of Schizophrenia: a narrative review. Adv Ther. 2022;39(11):4875–91.

Article  PubMed  PubMed Central  Google Scholar 

Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for Schizophrenia: an overview. CNS Drugs. 2021;35(1):39–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2):220–30.

Article  PubMed  Google Scholar 

European Medicines Agency. European Medicines Agency Report: Okedi (risperidone) medicine overview and marketing authorization information. 2022 https://www.ema.europa.eu/en/medicines/human/EPAR/okedi. 23 Jun 2023.

Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, Torres F, et al. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Filts Y, Litman RE, Martínez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83–91.

Article  CAS  PubMed  Google Scholar 

Jann MW, Penzak SR. Long-Acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs. 2018;32(3):241–57.

Article  CAS  PubMed  Google Scholar 

Janzen D, Bolton JM, Leong C, Kuo IF, Alessi-Severini S. Second-generation long-acting injectable antipsychotics and the risk of treatment failure in a population-based cohort. Front Pharmacol. 2022;13: 879224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020. https://doi.org/10.1002/14651858.CD008016.pub3.

Article  PubMed  PubMed Central  Google Scholar 

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2–3):107–17.

Article  PubMed  Google Scholar 

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25(5):685–97.

Article  CAS  PubMed  Google Scholar 

Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):1339.

Article  Google Scholar 

Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107–18.

Article  CAS  PubMed  Google Scholar 

Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135–44.

Article  PubMed  Google Scholar 

Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.

Article  PubMed  Google Scholar 

Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68(8):1163–71.

Article  PubMed  Google Scholar 

Begemann MJ, Thompson IA, Veling W, Gangadin SS, Geraets CN, Van’t Hag E, et al. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. Trials. 2020;21(1):1–19.

Article  Google Scholar 

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13(2):261–76.

Article  CAS  PubMed  Google Scholar 

Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016. (Technical Support Documents). NICE Decision Support Unit.

EUnetHTA. Direct and indirect comparisons. European Network for Health Technology Assessment. 2022.

Guy W. The clinician global severity and impression scales. ECDEU Assessment Manual for Psychopharmacology. 1979:218–22.

Team RC. R: A language and environment for statistical computing. 2013.

Zeileis A, Hothorn T. Diagnostic checking in regression relationships. 2002.

Zeileis A, Köll S, Graham N. Various versatile variances: an object-oriented implementation of clustered covariances in R. J Stat Softw. 2020;95:1–36.

Article  Google Scholar 

Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686.